EGFR and neoplasm: In contrast to tissue-based biopsy sampling of a single lesion, ctDNA-based assays can enable real-time detection of tumour heterogeneity as it evolves as well as the identification of alterations in RAS and the ECD of EGFR that might coexist after anti-EGFR therapy93–95,100,101.